Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.27 USD

5.27
5,686

+0.05 (0.96%)

Updated May 31, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Kamada Ltd. [KMDA]

Reports for Purchase

Showing records 21 - 37 ( 37 total )

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 21

12/23/2019

Company Report

Pages: 6

Looking to 2020 with Phase 3 InnovAATe Trial Progress in AATD, and Further FDA Feedback; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 22

08/07/2019

Company Report

Pages: 6

Human Factor Study Progress and Anticipated ?19 IND Filing for Inhaled AAT; Reit Buy and $11PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 23

07/10/2019

Industry Report

Pages: 4

KOL Reception and Dinner on Alpha-1 Antitrypsin Deficiency (AATD)

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 24

05/17/2019

Company Report

Pages: 6

Reiterated Revenue Guidance, Pivotal Phase 3 Trial for Inhaled AAT Expected This Year; Reit Buy and $11 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 25

02/14/2019

Company Report

Pages: 6

Underlying Revs Remain Strong While Strategic Value of Inhaled AAT Asset Remains Underappreciated in Our View

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 26

11/13/2018

Company Report

Pages: 7

Continue to Await Clarity on Path Forward for Inhaled AAT Program in the US

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 27

08/08/2018

Company Report

Pages: 5

Pipeline Steadily Progresses on the Foundation of Positive Cash Flows

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 28

02/08/2018

Company Report

Pages: 5

Experiencing Strong Growth and Perched on the Edge of Several Significant Data Readouts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 29

05/17/2017

Company Report

Pages: 6

AATD and GvHD Coming Into Play on Top of Reliable Underlying Business

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 30

02/07/2017

Company Report

Pages: 7

We Expect Cash Flow Positive 4Q17, as Clinical Pipeline Advances: Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 31

09/01/2016

Company Report

Pages: 7

Phase 2 Results: A Step in the Right Direction to Value

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 32

05/17/2016

Industry Report

Pages: 48

Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector

Provider: H.C. Wainwright & Co., Inc.

Price: 100.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 33

02/10/2016

Company Report

Pages: 7

The Year Ahead: Likely Progress Towards Righting the Ship, We Believe

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 34

07/31/2015

Company Report

Pages: 7

Our View on the Road Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 35

05/21/2015

Company Report

Pages: 6

Phase 2/3 Data Updates at ATS Continue to Support the Clinical Benefit of Inhaled AAT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 36

02/12/2015

Company Report

Pages: 7

Our View on the Road Ahead

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Kamada Ltd.

Industry: Medical - Biomedical and Genetics

Record: 37

11/13/2014

Company Report

Pages: 6

It?s Not You, It?s Me-The Bullish Prospect for a Potential Partnership

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party